Anne Sophie Czerniak

Ms. Anne Sophie Czerniak

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TFTobias Fischer
Tobias Fischer
ACAnne Sophie Czerniak
Anne Sophie Czerniak
TWTina Weiß
Tina Weiß
TZTristan Zellmann
Tristan Zellmann
Lina ZielkeLina Zielke
Lina Zielke
ABAnnette Beck-Sickinger
Annette Beck-Sickinger
Chemerin is a small chemotactic protein and a modulator of the innate immune system. Its activity is mainly mediated by the chemokine-like receptor 1 (CMKLR1), a receptor expressed by natural killer cells, dendritic cells, and macrophages. Downregulation of chemerin is part of the immune evasion strategy exploited by several cancer types, including melanoma, breast cancer, and hepatocellular carcinoma. Administration of chemerin can potentially counteract these effects, but synthetically accessible, metabolically stable analogs are required. Other tumors display overexpression of CMKLR1, offering a potential entry point for targeted delivery of chemotherapeutics. Here, we present cyclic derivatives of the chemerin C-terminus (chemerin-9), the minimal activation sequence of chemerin. Chemerin-9 derivatives that were cyclized through positions four and nine retained activity while displaying full stability in blood plasma for more than 24 h. Therefore, these peptides could be used as a drug shuttle system to target cancer cells as demonstrated here by methotrexate conjugates.

26 October 2022 in ChemMedChem
Verified
Journal Article
Open access
ACAnne Sophie Czerniak
Anne Sophie Czerniak
KKKevin Kretschmer
Kevin Kretschmer
TWTina Weiß
Tina Weiß
ABAnnette Beck-Sickinger
Annette Beck-Sickinger
To study the binding mode of the adipokine chemerin as well as the short peptide agonist chemerin‐9 (C9) to its two receptors chemokine‐like receptor 1 (CMKLR1) and G protein‐coupled receptor 1 (GPR1), we generated 5‐carboxytetramethylrhodamine (TAMRA) modified variants of both ligands. In addition, we labeled GPR1 and CMKLR1 with a nanoluciferase at the N‐terminus to perform NanoBRET binding assays. For GPR1, both ligands show high affinity and comparable binding. Significant differences were found for CMKLR1, whereby only full‐length chemerin binds with high affinity in saturation and displacement assays. For TAMRA‐C9 a biphasic binding consisting of two binding states has been found and no displacement studies could be performed. Thus, we conclude that CMKLR1 requires full‐length chemerin for stable binding in contrast to GPR1. This work demonstrates the NanoBRET binding assay as a new tool for binding studies at chemerin receptors and it enables deeper insights into the ligand binding parameters.